Key facts
- This page summarizes Marc Rubin's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Jan 2025, 16:07.
Marc Rubin - 23 Jan 2025 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)
- Reporting relationship
- Director
- Issuer ticker
- GALT
- Reported as of
- 23 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jan 2025, 16:07:38 UTC
- Prior SEC filing
- 23 May 2024
- Next SEC filing
- 30 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- Jack W. Callicutt, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Marc Rubin filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 27 Jan 2025.
Change
- Previous filing in this sequence was filed on 23 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GALT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- Price
- $0.000000
- Shares after
- 60,000
- Date
- 23 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $1.23
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
Footnote F2
The options vest 100% on December 31, 2025.